Investing in the AI Transformation of Pharma
Webinar details
marzo 17, 2026
11:00 US ET
Duración 30 MIN
Artificial intelligence is rapidly changing the pharmaceutical industry, transforming how drugs are discovered, designed, and tested. By analyzing massive biological datasets, AI is helping pharma companies identify promising drug targets faster, reduce early-stage failure rates, and improve clinical trial efficiency. Over time, these advances could meaningfully improve R&D productivity and strengthen the growth outlook for large pharma and biotech companies. We believe this reinforces the long-term investment case for the VanEck Biotech ETF (BBH) and VanEck Pharmaceutical ETF (PPH).
- AI is improving drug discovery efficiency by increasing early-stage success rates and reducing the cost and time required to bring new therapies to market.
- Smarter trial design and patient selection powered by AI may help improve overall pipeline outcomes and capital efficiency across the industry.
- For investors, large, diversified pharma and biotech firms are well-positioned to benefit as AI becomes embedded across R&D and operations.
La grabación estará disponible bajo demanda justo después del seminario en vivo.
